Blinatumomab in B-ALL: BiTE Structure, Mechanism, Resistance & Trials
Author: Alisha G C Abstract Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody that has fundamentally reshaped the therapeutic landscape of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). By physically linking endogenous cytotoxic T cells to CD19-expressing malignant B cells, Blinatumomab enables potent, major histocompatibility complex (MHC)–independent T-cell cytotoxicity, thereby overcoming critical limitations […]
Blinatumomab in B-ALL: BiTE Structure, Mechanism, Resistance & Trials Read More »









